Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

  • STATUS
    Recruiting
  • End date
    Nov 1, 2023
  • participants needed
    30
  • sponsor
    TaiRx, Inc.
Updated on 1 September 2021
cancer
small molecule
somatostatin
serum bilirubin
progressive disease
neutrophil count
neuroendocrine tumor

Summary

CVM-1118 (TRX-818) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objectives of the phase 2 study is to further investigate the efficacy of CVM-1118 for patients with advanced neuroendocrine tumors.

Description

Neuroendocrine tumors (NETs) are a group of uncommon heterogeneous malignancies originating from neuroendocrine cells localized throughout the body. Approximately 50% of patients with NETs would have metastatic cancer, where 65% of patients with metastatic cancer would result in mortality within 5 years of diagnosis.

The current treatments of NETs do not follow single discipline and the effective agents are largely still under clinical investigations. Apparent formation of vasculogenic mimicry (VM) has been reported in at least two types of NETs. Moreover, VM has been found as part of multiple microvascular alterations in mouse models of pancreatic neuroendocrine tumors.

Wih the high potential of inhibiting VM formation, CVM-1118 is considered to have therapeutic potentials in treating NET tumors.

Details
Condition Neuroendocrine Tumor, Islet Cell Tumor, Neuroectodermal Tumor, Neuroendocrine carcinoma, Pancreatic NET, Lung Neuroendocrine Neoplasm, Neurectoderma, Gastro-enteropancreatic Neuroendocrine Tumor, Gastro-enteropancreatic Neuroendocrine Tumor, Gastro-enteropancreatic Neuroendocrine Tumor, pancreatic neuroendocrine tumor, neuroendocrine tumors, neuroendocrine tumour, Gastro-enteropancreatic Neuroendocrine Tumor, Gastro-enteropancreatic Neuroendocrine Tumor, Gastro-enteropancreatic Neuroendocrine Tumor, Gastro-enteropancreatic Neuroendocrine Tumor
Treatment CVM-1118
Clinical Study IdentifierNCT03600233
SponsorTaiRx, Inc.
Last Modified on1 September 2021

Eligibility

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note